✦ LIBER ✦

Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasms

✍ Scribed by Mehrdad Nadji; Seyed Z. Tabei; Albert Castro; T. Ming Chu; Gerald P. Murphy; Ming C. Wang; Azorides R. Morales

Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 454 KB
Volume: 48
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19810901)48:5<1229::aid-cncr2820480529>3.0.co;2-l

No coin nor oath required. For personal study only.

✦ Synopsis

Antiserum to a human prostate-specific antigen was raised in a rabbit and utilized by immunoperoxidase staining to evaluate its potential value as a diagnostic histologic marker for tumors of prostatic origin. All primary and metastatic prostatic malignancies reacted positively, whereas nonprostatic neoplasms did not stain with this procedure. This is the first immunohistochemical marker for prostate gland epithelium which does not represent prostatic acid phosphatase.

📜 SIMILAR VOLUMES

Prostate-specific antigen. An important

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

✍ Gunar K. Zagars; Andrew C. von Eschenbach 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 1007 KB

Evaluation and comparison of two new pro

Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen

✍ Gerald P. Murphy; Robert J. Barren; Sheila J. Erickson; Victoria A. Bowes; Rober 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 816 KB

## BACKGROUND. Two new prostate cancer markers, free-prostate specific antigen (f-PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two-year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.

Screening for prostate carcinoma : Prost

Screening for prostate carcinoma : Prostate-specific antigen: Friend or foe?

✍ Anthony V. D'Amico 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 1 views

Anti–prostate-Specific membrane antigen-

Anti–prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer

✍ Scott T. Tagawa; Himisha Beltran; Shankar Vallabhajosula; Stanley J. Goldsmith; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

## Abstract Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostate‐specific membrane antigen (PSMA) shows promise and is an area of active investigation. J591 is a deimmunized Ig

Radiotherapy for localized prostate carc

Radiotherapy for localized prostate carcinoma : The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

✍ Juanita M. Crook; Yasir A. Bahadur; R. Gregory Bociek; Gad A. Perry; Susan J. Ro 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru

The fall and rise of prostate-specific a

The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

✍ Gunar K. Zagars; Alan Pollack 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 890 KB

Background. The serum kinetics of prostate-specific antigen (PSA) after radiation therapy for prostate cancer are not well characterized, and the potential prognostic significance of serum half-lives and of serum doubling times is unclear. This study was designed to address those issues. Methods. O